This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Cardinal Health's (CAH) Velocare to Enhance at-Home Care
by Zacks Equity Research
Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.
3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
by Zacks Equity Research
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.
What Makes AMN Healthcare (AMN) a Good Fit for "Trend Investing"
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AMN Healthcare (AMN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits
by Zacks Equity Research
Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.
Patterson Companies' (PDCO) New Buyout to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut
by Zacks Equity Research
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
by Zacks Equity Research
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
by Zacks Equity Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
Patterson Companies (PDCO) Inks Deal to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.
BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.